GlassScriptPhysician profile
Jacqueline Witt
NPI 1811457567
$9,419.17
in general payments reported to CMS, 2019-2025
28 companies · $3,786 in 2025
The $3,786 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $684 · 2023: $1,343 · 2024: $3,606 · 2025: $3,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,726 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,725.72 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,262.81 | 2022-2025 | Rinvoq, Skyrizi |
| Revance Therapeutics, INC. | $951.47 | 2024-2025 | Daxxify, Daxi |
| Genzyme Corporation | $704.45 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $698.79 | 2023-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $673.19 | 2023-2025 | Zoryve |
| Incyte Corporation | $586.27 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $564.66 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $554.57 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $423.94 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $407.23 | 2022-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $382.88 | 2023-2025 | Arazlo, Jublia, Siliq |
| Novartis Pharmaceuticals Corporation | $380.65 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $350.59 | 2022-2024 | Ilumya, Winlevi, Absorica Ld |
| Mayne Pharma Commercial LLC | $264.59 | 2023-2025 | |
| Pfizer INC. | $207.50 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $190.08 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $179.98 | 2022-2025 | Sotyktu |
| Organon LLC | $168.98 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $123.29 | 2023 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.82 | 2024-2025 | Spevigo |
| Galderma Laboratories, L.P. | $61.31 | 2022-2025 | Nemluvio |
| Botanix Sb INC | $49.14 | 2025 | Sofdra |
| Journey Medical Corporation | $39.61 | 2023-2024 | |
| Genentech USA, INC. | $24.83 | 2022 | |
| Verrica Pharmaceuticals INC. | $24.46 | 2024 | Ycanth |
| Leo Pharma INC. | $20.98 | 2023 | Adbry |
| Helsinn Therapeutics (U.S.), INC. | $17.58 | 2023 | Valchlor |
| Solta Medical, A Division of Bausch Health US, LLC | $17.52 | 2024 | Fraxel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.